Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

Abbott Laboratories Remains Structurally Undervalued

AI-generated analysis

📈 Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals.

💰 The stock trades at a 17.1% P/E and 35.1% sales multiple discount compared to peers.

🚀 DCF fair value estimates imply 21.8–39.4% upside potential for the company.

🔬 Growth is underpinned by the Exact Sciences acquisition and diagnostics megatrends.

🌍 Global expansion in Continuous Glucose Monitoring (CGM) supports future revenue growth.

📊 FY26 guidance has been raised for both sales and earnings per share (EPS).

🎯 Analyst consensus is bullish with forward 1Y price targets averaging $116.32.

🛡️ Medical devices are noted as resilient to broader macroeconomic market swings.

Bullish Signals
  • Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action.
  • The stock trades at a significant discount to peers with a 17.1% P/E ratio and a 35.1% sales multiple discount.
  • DCF fair value estimates imply substantial upside ranging from 21.8% to 39.4%.
  • Growth is underpinned by the strategic Exact Sciences acquisition and diagnostics megatrends.
  • Global expansion in Continuous Glucose Monitoring (CGM) provides a strong growth vector.
  • FY26 guidance has been raised for both sales and EPS, indicating improved outlook.
  • Analyst consensus is bullish with forward 1Y price targets averaging $116.32.
  • The medical device subsector offers resilience against broader macroeconomic swings.
Full Analysis
Abbott Laboratories (ABT) is characterized as a strong buy due to its structural undervaluation and resilient fundamentals, despite recent negative price action. The stock currently trades at a 17.1% P/E ratio and a 35.1% sales multiple discount relative to peers. Discounted Cash Flow (DCF) fair value estimates suggest potential upside ranging from 21.8% to 39.4%. Growth prospects for the company are driven by several key factors, including the acquisition of Exact Sciences, participation in diagnostics megatrends, and global expansion within Continuous Glucose Monitoring (CGM). Consequently, guidance for both sales and earnings per share (EPS) for fiscal year 2026 has been raised. Analyst consensus remains bullish with forward one-year price targets averaging $116.32, supporting a potential re-rating of the stock. Like other medical device subsectors in healthcare, Abbott is viewed as resilient to broader macroeconomic swings that often affect the rest of the market.